行情

CTIC

CTIC

CTi Biopharma
NASDAQ

实时行情|Nasdaq Last Sale

0.9580
+0.0280
+3.01%
已收盘, 16:00 04/02 EDT
开盘
0.9300
昨收
0.9300
最高
0.9700
最低
0.9300
成交量
14.59万
成交额
--
52周最高
1.930
52周最低
0.6200
市值
7,058.42万
市盈率(TTM)
-1.3878
分时
5日
1月
3月
1年
5年

分析师评级

2位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测CTIC价格均价为3.750,最高价位4.000,最低价为3.500。

EPS

CTIC 新闻

更多
  • 瑞幸爆出财务造假丑闻 股价一度狂跌八成
  • 新浪美股 · 1小时前
  • 特朗普称沙特和俄罗斯同意减产约1000万桶 但消息未获沙特证实
  • 新浪美股 · 1小时前
  • 特朗普宣称石油减产遭“打脸” 油价经历过山车行情
  • 新浪财经-自媒体综合 · 1小时前
  • 午后:油价大起大落 美股涨幅收窄
  • 新浪美股 · 1小时前

所属板块

生物技术和医学研究
+2.81%
制药与医学研究
+2.55%

热门股票

代码
价格
涨跌幅

CTIC 简况

CTI BioPharma Corp. is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies covering a spectrum of blood-related cancers to patients and healthcare providers. The Company is primarily focused on commercializing PIXUVRI in select countries in the European Union, for multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL). It is also engaged in evaluating pacritinib for the treatment of adult patients with myelofibrosis. Its earlier stage product candidate, tosedostat, is an oral, once-daily aminopeptidase inhibitor that has demonstrated responses in patients with acute myeloid leukemia (AML). It also evaluates its pipeline candidate paclitaxel poliglumex (Opaxio), which targets solid tumors. It is evaluating Opaxio through cooperative group sponsored trials and investigator-sponsored trials (IST), such as the ongoing maintenance therapy trial in patients with ovarian cancer.
展开

微牛提供CTI BioPharma Corp(NASDAQ-CTIC)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的CTIC股票新闻,以帮助您做出投资决策。